ID   PK3CA_RAT               Reviewed;        1068 AA.
AC   A0A0G2K344;
DT   16-MAR-2016, integrated into UniProtKB/Swiss-Prot.
DT   22-JUL-2015, sequence version 1.
DT   24-JUL-2024, entry version 61.
DE   RecName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform {ECO:0000312|RGD:620916};
DE            Short=PI3-kinase subunit alpha {ECO:0000305};
DE            Short=PI3K-alpha {ECO:0000305};
DE            Short=PI3Kalpha {ECO:0000305};
DE            Short=PtdIns-3-kinase subunit alpha {ECO:0000305};
DE            EC=2.7.1.137 {ECO:0000250|UniProtKB:P42336};
DE            EC=2.7.1.153 {ECO:0000250|UniProtKB:P42336};
DE   AltName: Full=Phosphatidylinositol 4,5-bisphosphate 3-kinase 110 kDa catalytic subunit alpha {ECO:0000305};
DE            Short=PtdIns-3-kinase subunit p110-alpha {ECO:0000305};
DE            Short=p110alpha {ECO:0000303|PubMed:20236230};
DE   AltName: Full=Phosphoinositide-3-kinase catalytic alpha polypeptide {ECO:0000305};
DE   AltName: Full=Serine/threonine protein kinase PIK3CA {ECO:0000305};
DE            EC=2.7.11.1 {ECO:0000250|UniProtKB:P32871};
GN   Name=Pik3ca {ECO:0000312|RGD:620916};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116 {ECO:0000312|Proteomes:UP000002494};
RN   [1] {ECO:0000312|Proteomes:UP000002494}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway {ECO:0000312|Proteomes:UP000002494};
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [2] {ECO:0000305}
RP   FUNCTION, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley {ECO:0000303|PubMed:20236230};
RX   PubMed=20236230; DOI=10.1111/j.1365-2826.2010.01975.x;
RA   Tups A., Anderson G.M., Rizwan M., Augustine R.A., Chaussade C.,
RA   Shepherd P.R., Grattan D.R.;
RT   "Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase
RT   are required for insulin signalling in the hypothalamus.";
RL   J. Neuroendocrinol. 22:534-542(2010).
CC   -!- FUNCTION: Phosphoinositide-3-kinase (PI3K) phosphorylates
CC       phosphatidylinositol (PI) and its phosphorylated derivatives at
CC       position 3 of the inositol ring to produce 3-phosphoinositides. Uses
CC       ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to
CC       generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a
CC       key role by recruiting PH domain-containing proteins to the membrane,
CC       including AKT1 and PDPK1, activating signaling cascades involved in
CC       cell growth, survival, proliferation, motility and morphology.
CC       Participates in cellular signaling in response to various growth
CC       factors. Involved in the activation of AKT1 upon stimulation by
CC       receptor tyrosine kinases ligands such as EGF, insulin, IGF1, VEGFA and
CC       PDGF. Involved in signaling via insulin-receptor substrate (IRS)
CC       proteins (PubMed:20236230). Essential in endothelial cell migration
CC       during vascular development through VEGFA signaling, possibly by
CC       regulating RhoA activity. Required for lymphatic vasculature
CC       development, possibly by binding to RAS and by activation by EGF and
CC       FGF2, but not by PDGF. Regulates invadopodia formation through the
CC       PDPK1-AKT1 pathway. Participates in cardiomyogenesis in embryonic stem
CC       cells through a AKT1 pathway. Participates in vasculogenesis in
CC       embryonic stem cells through PDK1 and protein kinase C pathway. In
CC       addition to its lipid kinase activity, it displays a serine-protein
CC       kinase activity that results in the autophosphorylation of the p85alpha
CC       regulatory subunit as well as phosphorylation of other proteins such as
CC       4EBP1, H-Ras, the IL-3 beta c receptor and possibly others (By
CC       similarity). Plays a role in the positive regulation of phagocytosis
CC       and pinocytosis (By similarity). {ECO:0000250|UniProtKB:P42336,
CC       ECO:0000250|UniProtKB:P42337, ECO:0000269|PubMed:20236230}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836,
CC         ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153;
CC         Evidence={ECO:0000250|UniProtKB:P42336};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293;
CC         Evidence={ECO:0000250|UniProtKB:P42336};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a
CC         1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP +
CC         H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216;
CC         EC=2.7.1.137; Evidence={ECO:0000250|UniProtKB:P42336};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710;
CC         Evidence={ECO:0000250|UniProtKB:P42336};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000250|UniProtKB:P32871};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000250|UniProtKB:P32871};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + ATP = 1,2-dioctanoyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:55632,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:83416,
CC         ChEBI:CHEBI:83419, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000250|UniProtKB:P42336};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55633;
CC         Evidence={ECO:0000250|UniProtKB:P42336};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-octadecanoyl-2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-
CC         3-phospho-1D-myo-inositol 4,5-bisphosphate + ATP = 1-octadecanoyl-2-
CC         (5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phospho-(1D-myo-
CC         inositol 3,4,5-triphosphate) + ADP + H(+); Xref=Rhea:RHEA:43396,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:77137,
CC         ChEBI:CHEBI:83243, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000250|UniProtKB:P42336};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:43397;
CC         Evidence={ECO:0000250|UniProtKB:P42336};
CC   -!- PATHWAY: Phospholipid metabolism; phosphatidylinositol phosphate
CC       biosynthesis. {ECO:0000250|UniProtKB:P42336}.
CC   -!- SUBUNIT: Heterodimer of a catalytic subunit PIK3CA and a p85 regulatory
CC       subunit (PIK3R1, PIK3R2 or PIK3R3). Interacts with IRS1 in nuclear
CC       extracts. Interacts with RUFY3. Interacts with RASD2. Interacts with
CC       APPL1. Interacts with HRAS and KRAS. Interaction with HRAS/KRAS is
CC       required for PI3K pathway signaling and cell proliferation stimulated
CC       by EGF and FGF2. Interacts with FAM83B; activates the PI3K/AKT
CC       signaling cascade. {ECO:0000250|UniProtKB:P42336,
CC       ECO:0000250|UniProtKB:P42337}.
CC   -!- TISSUE SPECIFICITY: Detected in the hypothalamus (at protein level).
CC       {ECO:0000269|PubMed:20236230}.
CC   -!- DOMAIN: The PI3K-ABD domain and the PI3K-RBD domain interact with the
CC       PI3K/PI4K kinase domain. The C2 PI3K-type domain may facilitate the
CC       recruitment to the plasma membrane. The inhibitory interactions with
CC       PIK3R1 are mediated by the PI3K-ABD domain and the C2 PI3K-type domain
CC       with the iSH2 (inter-SH2) region of PIK3R1, and the C2 PI3K-type
CC       domain, the PI3K helical domain, and the PI3K/PI4K kinase domain with
CC       the nSH2 (N-terminal SH2) region of PIK3R1.
CC       {ECO:0000250|UniProtKB:P42336}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00877}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AABR07009968; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; NP_596890.2; NM_133399.2.
DR   AlphaFoldDB; A0A0G2K344; -.
DR   SMR; A0A0G2K344; -.
DR   IntAct; A0A0G2K344; 3.
DR   STRING; 10116.ENSRNOP00000072496; -.
DR   BindingDB; A0A0G2K344; -.
DR   ChEMBL; CHEMBL5169092; -.
DR   iPTMnet; A0A0G2K344; -.
DR   PhosphoSitePlus; A0A0G2K344; -.
DR   jPOST; A0A0G2K344; -.
DR   PaxDb; 10116-ENSRNOP00000014527; -.
DR   Ensembl; ENSRNOT00000083720.2; ENSRNOP00000072496.1; ENSRNOG00000056371.2.
DR   Ensembl; ENSRNOT00055017425; ENSRNOP00055014022; ENSRNOG00055010309.
DR   Ensembl; ENSRNOT00060003682; ENSRNOP00060002555; ENSRNOG00060002338.
DR   Ensembl; ENSRNOT00065013857; ENSRNOP00065010305; ENSRNOG00065008709.
DR   GeneID; 170911; -.
DR   KEGG; rno:170911; -.
DR   AGR; RGD:620916; -.
DR   CTD; 5290; -.
DR   RGD; 620916; Pik3ca.
DR   eggNOG; KOG0904; Eukaryota.
DR   GeneTree; ENSGT00940000155531; -.
DR   InParanoid; A0A0G2K344; -.
DR   OMA; WSEWLNY; -.
DR   OrthoDB; 10350at2759; -.
DR   BRENDA; 2.7.1.153; 5301.
DR   Reactome; R-RNO-109704; PI3K Cascade.
DR   Reactome; R-RNO-112399; IRS-mediated signalling.
DR   Reactome; R-RNO-114604; GPVI-mediated activation cascade.
DR   Reactome; R-RNO-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-RNO-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-RNO-1433557; Signaling by SCF-KIT.
DR   Reactome; R-RNO-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-RNO-180292; GAB1 signalosome.
DR   Reactome; R-RNO-186763; Downstream signal transduction.
DR   Reactome; R-RNO-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-RNO-198203; PI3K/AKT activation.
DR   Reactome; R-RNO-201556; Signaling by ALK.
DR   Reactome; R-RNO-202424; Downstream TCR signaling.
DR   Reactome; R-RNO-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-RNO-210993; Tie2 Signaling.
DR   Reactome; R-RNO-2424491; DAP12 signaling.
DR   Reactome; R-RNO-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-RNO-388841; Costimulation by the CD28 family.
DR   Reactome; R-RNO-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   Reactome; R-RNO-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-RNO-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-RNO-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-RNO-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-RNO-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-RNO-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-RNO-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-RNO-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-RNO-8851907; MET activates PI3K/AKT signaling.
DR   Reactome; R-RNO-8853659; RET signaling.
DR   Reactome; R-RNO-9009391; Extra-nuclear estrogen signaling.
DR   Reactome; R-RNO-9013149; RAC1 GTPase cycle.
DR   Reactome; R-RNO-9013404; RAC2 GTPase cycle.
DR   Reactome; R-RNO-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K).
DR   Reactome; R-RNO-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-RNO-912631; Regulation of signaling by CBL.
DR   Reactome; R-RNO-9607240; FLT3 Signaling.
DR   Reactome; R-RNO-9842663; Signaling by LTK.
DR   UniPathway; UPA00220; -.
DR   PRO; PR:A0A0G2K344; -.
DR   Proteomes; UP000002494; Chromosome 2.
DR   Bgee; ENSRNOG00000056371; Expressed in thymus and 19 other cell types or tissues.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0014704; C:intercalated disc; ISO:RGD.
DR   GO; GO:0030027; C:lamellipodium; ISO:RGD.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IDA:RGD.
DR   GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; ISO:RGD.
DR   GO; GO:0005944; C:phosphatidylinositol 3-kinase complex, class IB; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:RGD.
DR   GO; GO:0046934; F:1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity; ISO:RGD.
DR   GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043560; F:insulin receptor substrate binding; ISO:RGD.
DR   GO; GO:0016301; F:kinase activity; ISO:RGD.
DR   GO; GO:0030295; F:protein kinase activator activity; ISO:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0030036; P:actin cytoskeleton organization; ISO:RGD.
DR   GO; GO:0060612; P:adipose tissue development; ISO:RGD.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0141068; P:autosome genomic imprinting; ISO:RGD.
DR   GO; GO:0086003; P:cardiac muscle cell contraction; ISO:RGD.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; ISO:RGD.
DR   GO; GO:0071464; P:cellular response to hydrostatic pressure; ISO:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; ISO:RGD.
DR   GO; GO:0097009; P:energy homeostasis; ISO:RGD.
DR   GO; GO:0006006; P:glucose metabolic process; ISO:RGD.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0001889; P:liver development; ISO:RGD.
DR   GO; GO:0030835; P:negative regulation of actin filament depolymerization; ISO:RGD.
DR   GO; GO:2000811; P:negative regulation of anoikis; ISO:RGD.
DR   GO; GO:2000270; P:negative regulation of fibroblast apoptotic process; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; IGI:BHF-UCL.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; ISO:RGD.
DR   GO; GO:0006909; P:phagocytosis; IEA:UniProtKB-KW.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISO:RGD.
DR   GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; IDA:RGD.
DR   GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central.
DR   GO; GO:0016310; P:phosphorylation; IEA:Ensembl.
DR   GO; GO:0051897; P:positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISO:RGD.
DR   GO; GO:1905477; P:positive regulation of protein localization to membrane; ISO:RGD.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0110053; P:regulation of actin filament organization; ISO:RGD.
DR   GO; GO:0043457; P:regulation of cellular respiration; ISO:RGD.
DR   GO; GO:0010468; P:regulation of gene expression; ISO:RGD.
DR   GO; GO:0040014; P:regulation of multicellular organism growth; ISO:RGD.
DR   GO; GO:0001932; P:regulation of protein phosphorylation; ISO:RGD.
DR   GO; GO:0055119; P:relaxation of cardiac muscle; ISO:RGD.
DR   GO; GO:0014823; P:response to activity; IEP:RGD.
DR   GO; GO:1903544; P:response to butyrate; IEP:RGD.
DR   GO; GO:0071548; P:response to dexamethasone; IEP:RGD.
DR   GO; GO:0043201; P:response to L-leucine; IEP:RGD.
DR   GO; GO:0014870; P:response to muscle inactivity; IEP:RGD.
DR   GO; GO:0035994; P:response to muscle stretch; ISO:RGD.
DR   GO; GO:0038084; P:vascular endothelial growth factor signaling pathway; ISO:RGD.
DR   CDD; cd08398; C2_PI3K_class_I_alpha; 1.
DR   CDD; cd00872; PI3Ka_I; 1.
DR   CDD; cd05175; PI3Kc_IA_alpha; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1.
DR   Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR036940; PI3/4_kinase_cat_sf.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR002420; PI3K-type_C2_dom.
DR   InterPro; IPR003113; PI3K_ABD.
DR   InterPro; IPR001263; PI3K_accessory_dom.
DR   InterPro; IPR042236; PI3K_accessory_sf.
DR   InterPro; IPR000341; PI3K_Ras-bd_dom.
DR   InterPro; IPR037704; PI3Kalpha_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR10048:SF107; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT ALPHA ISOFORM; 1.
DR   PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF02192; PI3K_p85B; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00143; PI3K_p85B; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 1.
DR   PROSITE; PS51547; C2_PI3K; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51544; PI3K_ABD; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
PE   1: Evidence at protein level;
KW   Angiogenesis; ATP-binding; Kinase; Nucleotide-binding; Phagocytosis;
KW   Proto-oncogene; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN           1..1068
FT                   /note="Phosphatidylinositol 4,5-bisphosphate 3-kinase
FT                   catalytic subunit alpha isoform"
FT                   /evidence="ECO:0000305"
FT                   /id="PRO_0000435723"
FT   DOMAIN          16..105
FT                   /note="PI3K-ABD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00877"
FT   DOMAIN          187..289
FT                   /note="PI3K-RBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00879"
FT   DOMAIN          330..487
FT                   /note="C2 PI3K-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00880"
FT   DOMAIN          517..694
FT                   /note="PIK helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00878"
FT   DOMAIN          765..1051
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          771..777
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          912..920
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          931..957
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
SQ   SEQUENCE   1068 AA;  124354 MW;  C0C63273CF161F9C CRC64;
     MPPRPSSGEL WGIHLMPPRI LVECLLPNGM IVTLECLREA TLVTIKHELF KEARKYPLHQ
     LLQDESSYIF VSVTQEAERE EFFDETRRLC DLRLFQPFLK VIEPVGNREE KILNREIGFV
     IGMPVCEFDM VKDPEVQDFR RNILNVCKEA VDLRDLNSPH SRAMYVYPPN VESSPELPKH
     IYNKLDKGQI IVVIWVIVSP NNDKQKYTLK INHDCVPEQV IAEAIRKKTR SMLLSSEQLK
     LCVLEYQGKY ILKVCGCDEY FLEKYPLSQY KYIRSCIMLG RMPNLMLMAK ESLYSQLPID
     SFTMPSYSRR ISTATPYMNG ETATKSLWVI NSALRIKILC ATYVNVNIRD IDKIYVRTGI
     YHGGEPLCDN VNTQRVPCSN PRWNEWLNYD IYIPDLPRAA RLCLSICSVK GRKGAKEEHC
     PLAWGNINLF DYTDTLVSGK MALNLWPVPH GLEDLLNPIG VTGSNPNKET PCLELEFDWF
     SSVVKFPDMS VIEEHANWSV SREAGFSYSH TGLSNRLARD NELRENDKEQ LRALCTRDPL
     SEITEQEKDF LWSHRHYCVT IPEILPKLLL SVKWNSRDEV AQMYCLVKDW PPIKPEQAME
     LLDCNYPDPM VRSFAVRCLE KYLTDDKLSQ YLIQLVQVLK YEQYLDNLLV RFLLKKALTN
     QRIGHFFFWH LKSEMHNKTV SQRFGLLLES YCRACGMYLK HLNRQVEAME KLINLTDILK
     QEKKDETQKV QMKFLVEQMR QPDFMDALQG FLSPLNPAHQ LGNLRLEECR IMSSAKRPLW
     LNWENPDIMS ELLFQNNEII FKNGDDLRQD MLTLQIIRIM ENIWQNQGLD LRMLPYGCLS
     IGDCVGLIEV VRNSHTIMQI QCKGGLKGAL QFNSHTLHQW LKDKNKGEIY DAAIDLFTRS
     CAGYCVATFI LGIGDRHNSN IMVKDDGQLF HIDFGHFLDH KKKKFGYKRE RVPFVLTQDF
     LIVISKGAQE YTKTREFERF QEMCYKAYLA IRQHANLFIN LFSMMLGSGM PELQSFDDIA
     YIRKTLALDK TEQEALEYFT KQMNDAHHGG WTTKMDWIFH TIKQHALN
//
